2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

22 trials found

diseases per page:

Showing 1 to 10 of 22 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04849065 (ClinicalTrials.gov)	May 1, 2021	15/4/2021	Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Scle ...	Clinical Trial in Phase II of Intramuscular Infusion of Autologous Bone Marrow Stem Cellsin Patients ...	ALS (Amyotrophic Lateral Sclerosis)	Drug: MNC (Mononuclear cells);Drug: Placebo / Saline	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia	NULL	Not yet recruiting	18 Years	70 Years	All	100	Phase 2	Spain
2	NCT04681118 (ClinicalTrials.gov)	March 24, 2021	18/12/2020	Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Trea ...	Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (A ...	Amyotrophic Lateral Sclerosis	Biological: NurOwn (MSC-NTF cells)	Brainstorm-Cell Therapeutics	NULL	No longer available	18 Years	63 Years	All			United States
3	NCT04651855 (ClinicalTrials.gov)	December 2, 2020	30/9/2020	The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS	The Evaluation of the Effect of Wharton's Jelly Mesenchymal Stem Cells(WJMSCs) on the Immune System ...	Amyotrophic Lateral Sclerosis	Drug: Mesenchymal stem cells isolated from Wharton's jelly	Polski Bank Komorek Macierzystych JSC (PBKM)	National Center for Research and Development, Poland	Active, not recruiting	18 Years	N/A	All	20	Phase 1/Phase 2	Poland
4	EUCTR2018-004171-12-PL (EUCTR)	22/07/2020	05/09/2019	The evaluation of the effect of Wharton’s Jelly Mesenchymal Stem Cells(WJMSCs) on the immune system ...	The evaluation of the effect of Wharton’s Jelly Mesenchymal Stem Cells(WJMSCs) on the immune system ...	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Product Name: FamC-1 INN or Proposed INN: WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELLS Other descrip ...	Polski Bank Komórek Macierzystych JSC (PBKM)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 1;Phase 2	Poland
5	EUCTR2019-002302-46-ES (EUCTR)	23/10/2019	09/08/2019	Phase II clinical trial of intramuscular infusion of autologous bone marrow stem cellsin patients wi ...	Phase II clinical trial of intramuscular infusion of autologous bone marrow stem cellsin patients wi ...	Amyotrophic Lateral Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: autologous adult bone marrow mononuclear cells (BM-MNC) unexpanded INN or Proposed INN: ...	Fundación para la Formación e Investigación Sanitarias de la Región de Murcia	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Spain
6	NCT03482050 (ClinicalTrials.gov)	April 12, 2018	14/3/2018	A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patien ...	A Phase I/IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and T ...	ALS (Amyotrophic Lateral Sclerosis)	Biological: AstroRx	Kadimastem	NULL	Completed	18 Years	70 Years	All	16	Phase 1/Phase 2	Israel
7	NCT03280056 (ClinicalTrials.gov)	August 28, 2017	29/8/2017	Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients	A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Sa ...	Amyotrophic Lateral Sclerosis (ALS)	Biological: NurOwn® (MSC-NTF cells);Other: Placebo;Other: Bone Marrow aspiration	Brainstorm-Cell Therapeutics	California Institute for Regenerative Medicine (CIRM)	Completed	18 Years	60 Years	All	263	Phase 3	United States
8	NCT03067857 (ClinicalTrials.gov)	September 2016	25/2/2017	Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease	Autologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron Disease	Motor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular At ...	Biological: Stem Cells	Stem Cells Arabia	NULL	Unknown status	24 Years	70 Years	All	40	Phase 1/Phase 2	NULL
9	NCT04821479 (ClinicalTrials.gov)	January 1, 2016	19/10/2020	Repeated Mesenchymal Stem Cell Injections in ALS	Safety and Clinical Effects of Repeated Intrathecal Injections of Autologous Mesenchymal Stem Cellsi ...	Amyotrophic Lateral Sclerosis	Biological: Mesenchymal stem cells (MSC)	Hadassah Medical Organization	NULL	Completed	18 Years	65 Years	All	20	Phase 1/Phase 2	NULL
10	NCT02116634 (ClinicalTrials.gov)	May 2015	6/4/2014	Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis	Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients	Amyotrophic Lateral Sclerosis	Biological: mesenchymal stem cell	Alzahra Hospital, Iran	NULL	Withdrawn	18 Years	60 Years	Both	0	Phase 1/Phase 2	Iran, Islamic Republic of

First Previous1 2 3Next Last